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1. Introduction 
Although they tend to develop some independence upon malignant transformation, tumor
cells and tumors remain“social” moieties. In many steps during tumor progression, tumor
cells’ interaction with each other and with their microenvironment is an essential element in 
their survival, growth and progression. This dependence on cell-cell interactions provides 
an opportunity for therapeutic interventions. In addition to long range interactions through
growth factors, cytokines and other released molecules, the cells use various structures to 
interact directly, including gap junctions (GJ), tight junctions, adherens junctions and 
desmosomes. 
Gap junction intercellular communication (GJIC), is a process involved in the transfer of
second messengers such as cAMP, cGMP, glutamate, NAD+, IP3, glutathione, and Ca++ ions, 
between cells, through channel structures called gap junctions (GJ). It is involved in various
biological functions including regulation of cell growth, cell differentiation, and
maintenance of tissue homeostasis (Wei et al. 2004). Structurally, gap junctions are formed
by two head-to-head opposing hexameric transmembrane channels called connexons or 
hemichannels contributed by two interacting cells (Yeager and Harris 2007). The building 
units of connexons are the connexin proteins (Cxs), which are tetraspan integral membrane
proteins (Nakagawa et al. 2010). 
Expression and functional analysis of connexins and GJIC revealed that, in general, they are
lost in cancer (Kandouz and Batist 2010) and their restoration has tumor inhibitory effects, 
which led to the concept that this type of intercellular communication plays a tumor 
suppressor role. Consequently, it early became clear that restoring GJIC and connexin 
expression, using different chemical treatments or by gene transfer, can be used to inhibit 
tumor cell growth (Fernstrom et al. 2002). 
GJIC and Cxs have also been suggested to be involved during metastasis, although this role
is still largely unclear. For example, on one hand connexin43 (Cx43) affects angiogenesis in 
vitro and in vivo, via an effect on proteins such as the Monocyte chemotactic protein-1 (MCP­
1) and Interleukin-6 (McLachlan et al. 2006) , although this effect seems GJIC-independent 
(McLachlan et al. 2006) . On the other hand, Cx43-mediated GJIC facilitates metastatic 
homing to the lung via increased adhesion to endothelial cells (Elzarrad et al. 2008). GJIC as 
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218 Gene Therapy - Developments and Future Perspectives 
a result of overexpression of Cx43 in MDA-MET, an aggressive derivative of the metastatic 
breast cancer cell line MDA-MB-231, decreased cell invasion (Li et al. 2008a). Cx43 and Cx26
have been suggested to contribute to metastasis of breast cancer to the lymph nodes
(Kanczuga-Koda et al. 2006). 
However, although connexins and gap junctions are tightly associated, connexins are
capable of functions of their own. The exact role of GJIC-dependent versus –independent 
functions of connexins is still ill-understood and sometimes even paradoxical (Mesnil et al. 
2005) (Dbouk et al. 2009).  For example, connexins seem to act as tumor suppressors as well
as tumor facilitators in the breast (McLachlan et al. 2007). The above-mentioned role of Cx43 
in angiogenesis seems GJIC-independent (McLachlan et al. 2006). 
Visibly, more studies are needed to understand the complex role of GJIC and Cxs in cancer.
This lack of information is a major obstacle to the full use of the therapeutic potential of Cxs
and GJIC in cancer. Nevertheless, this obstacle didn’t prevent from a attempting many 
creative and promising therapeutic strategies. 
2. Connexins and GJIC in gene therapy: the bystander effect 
A major limitation to cancer gene therapy is the often limited transfection efficiency of target 
cells. This is the specific aspect where the field of gap junctions has been particularly
helpful, using a mechanism to amplify the cytotoxic signal originating from a limited 
population of target cells. 
2.1 Bystander effect-mediated functions of connexins and GJIC
For the GJIC researchers, it quickly became clear that the ability of cells to transmit signaling 
moieties to their neighbors would offer an interesting opportunity. This strategy, based on a 
process called “bystander effect” (BE) (Figure 1), doesn’t require the therapeutic agent to
reach all tumor cells (van, I et al. 2002). Thanks to the BE, triggering the death process in a
single cell could be amplified by transfer of the cytotoxic signaling molecules via the GJICs,
resulting in similar changes and fate in interacting cells. A major mechanism of the BE 
involves direct gap junctional intercellular communication (GJIC) and changes in connexins’
levels translate into changes in the BE potential (Asklund et al. 2003; Elshami et al. 1996; 
Yamasaki and Katoh 1988). Therefore, the BE is an important factor in the efficiency of 
cancer therapy (Mothersill and Seymour 2004), but its function requires direct intracellular 
contacts to undergo cytotoxicity. So far, a major application for the BE has been gene
therapy. Many authors have shown a decade ago that the BE promotes the so-called
“suicide gene therapy”. 
The first explorations of the BE therapeutic potential involved the use of enzyme/prodrug 
gene therapy approaches. In this therapy, target cells are made to express an enzyme that
converts a prodrug inside the cell into the cytotoxic active drug that is transmitted to and 
kills the interacting cells. Two combinations of enzymes and prodrugs have been
particularly tested: the bacterial cytosine deaminase (CD) with the antifungal drug 5­
fluorocytosine (CD/5-FC) and, most widely, the herpes simplex virus thymidine kinase
(HSVtk) with the antiherpetic ganciclovir (HSVtk/GCV) (Mesnil et al. 1996; Trinh et al. 
1995). In the CD/5-FC system, CD converts 5-FC into the active cytotoxic form 5­
fluorouracil (5-FU) (Mullen et al. 1992). While ganciclovir (GCV), a nucleoside analogue, is
poorly metabolized by mammalian thymidine kinases, it is phosphorylated by the HSVtk
and cellular kinases and thus converted into the nucleotide GCV triphosphate, a cytotoxic 
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219Hopes and Disillusions in Therapeutic Targeting of Intercellular Communication in Cancer
drug (Chen et al. 1994). The later works by incorporating into and blocking replication of
DNA in dividing cells, resulting in induction of cell death (Thompson 1999). The
phosphorylated form of GCV will be transmitted to neighboring cells via GJIC. For example, 
transfection of tumor cells expressing Cx43 with HSVtk will allow GCV to kill target as well
as by-standing cells (Mesnil et al. 1996). GJIC and connexins have been shown to be
involved during the BE-based HSV-tk/GCV therapy (Dilber et al. 1997; Vrionis et al. 1997; 
Elshami et al. 1996; Fick et al. 1995; Mesnil et al. 1996). BE using the UPRT/5-FU system 
(uracil phosphoribosyltransferase (UPRT) of E. coli origin and 5-fluorouracil (5-FU)) was 
found to be correlated to the level of Cx43 and GJIC (Kawamura et al. 2001). The extent of 
the role of GJIC and Cxs in BE-mediated cytotoxicity is most certainly underestimated. 
Many experimental therapeutic strategies make use of the BE but the role of GJICs or Cxs in 
their mechanism of action has not been investigated yet. 
Fig. 1. Bystander Effect. A death signal, such as the one from the enzyme/prodrug system, 
triggered in a single cell is transmitted, through GJIC-dependent or –independent 
mechanisms, to neighboring cells. These bystanding cells are, in turn, destined to die
without being directly targeted by the cytotoxic stimuli.
The efficacy of the enzyme/prodrug approach in vitro and in animal xenograft models has
been demonstrated (Xu and McLeod 2001). However, there are many factors which 
immediately affect the efficacy of the approach. Although the % of cells expressing either 
HSVtk or CD has been shown to have some importance, the extent of contacts between cells
was found to be the most crucial condition, as it requires contact between cells as well as
their ability to transfer small cytotoxic molecules from one to another (Bi et al. 1993; Fick et
al. 1995; Trinh et al. 1995). Using a murine breast cancer model transgenic for the activated
rat neu oncogene under the control of the mouse mammary tumor virus long terminal 
repeat (MMTV-LTR), the efficacy of the HSVtk/GCV system has been shown in vivo. 
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220 Gene Therapy - Developments and Future Perspectives 
However, this approach showed an incomplete antitumor potential, the limiting factors 
being low viral transduction efficiency and functionality of the BE and GJIC in mammary 
tumor cells (Sacco et al. 1996; Sacco et al. 1995). 
As previously stressed, there is need for further deciphering of the respective roles played
by GJIC, Cxs and the BE in these enzyme/prodrug systems in different cellular and cancer 
contexts. Characterizing the interdependence of the BE and GJIC in gene therapy systems
could allow their more effective use. It has been reported that the BE resulting from the
thymidine kinase/ganciclovir (tk/GCV) system requires functional GJIC while in the
thymidine phosphorylase/5′-deoxy-5-fluorouridine (tp/DFUR) system, whereas thymidine 
phosphorylase (TP) converts 5′-deoxy-5-fluorouridine (5′-DFUR, doxifluridine) to 5-FU and
its anabolite 5-fluoro-2′-deoxyuridine (5-FdUrd), the BE occurs via the cell culture medium 
and is independent of GJIC and apoptosis. Nevertheless, combining these two systems
showed more BE than each system separately (Denning and Pitts 1997). It has also been
reported that, in comparison to the HSVtk/GCV system, bystander killing resulting from 
the CD/5-FC system is GJIC-independent, and both communication-competent and ­
incompetent CD-transduced cells were killed dramatically more than bystander cells
(Lawrence et al. 1998). Shared culture medium rather than direct cell-cell contacts were 
incriminated in the BE-mediated cell killing (Bai et al. 1999). Taken together, these findings
particularly support the need for a better understanding of GJIC-independent BE to better 
rationalize the therapeutic use of this approach. This is particularly true when combining 
enzyme/prodrug targeting with connexin overexpression. 
2.2 Role of apoptosis in the bystander effect cytotoxicity
The cytotoxic effects of these enzyme/prodrug systems via the BE are due to the induction 
of apoptosis (Hamel et al. 1996). GJIC can either mediate apoptotic cell death or potentiate
the efficacy of pro-apoptotic agents. The BE allows these drugs or their signaling 
intermediates to reach by diffusion more cells than they would do alone (Peixoto et al. 2009)
(Jensen and Glazer 2004; Udawatte and Ripps 2005). In fact, it has been shown that gap
junctions remain open during the apoptotic process (Cusato et al. 2006). However, there are
additional, less understood mechanisms for the role of gap junctions in BE cytotoxicity. In 
other respect, the BE can be instrumental in drug resistance. For instance, Src activation 
induces Cx43 tyrosine phosphorylation and GJIC decrease, resulting in resistance to 
Cisplatin (Peterson-Roth et al. 2009). 
Therefore, one expected limitation to the enzyme/prodrug gene therapy approach would
come from the fact that in cancer cells, many apoptosis-related signaling pathways are often 
aberrant. It has been shown for example that HSV-tk/GCV-induced BE is influenced by 
mutations in p53 (van, I et al. 2005), a tumor suppressor gene frequently mutated in cancer 
and which regulates apoptotic cell death. A study by Garcia-Rodríguez et al. showed a
strong correlation of E-cadherin expression and the TK/GCV bystander effect and that
increasing the expression of E-cadherin improved TK/GCV cytotoxicity and triggered a 
potent antitumoral effect in vivo, through reduction of the anti-apoptotic protein Bcl-2 
(Garcia-Rodriguez et al. 2011a). Similarly, the efficacy of this gene therapy strategy could be
undermined by certain treatment combinations. Treatment with dexamethasone
significantly reduced their apoptotic response in glioma cells, as a result of diminished
GJIC-dependent BE and efficacy of HSVtk gene therapy (Robe et al. 2005). This finding 
warns against future usage of dexamethasone as a symptomatic treatment if HSVtk gene
therapy were to be attempted. Luckily, the outcome of this gene therapy strategy can also be 
improved by a multitude of other treatments (Robe et al. 2004) as will be discussed below. 
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3. Strategies to potentiate the bystander effect-based therapy
Attempts to use the BE in gene therapy studies are limited by the ability of target cells to
communicate by gap junctions. Restoring GJIC to these cells in the enzyme/prodrug 
systems could not only bypass this limitation, it by itself has a gene therapy potential 
(Figure 2). Indeed, two different approaches have been used in the literature: 1) intratumoral 
delivery of Cx-encoding vectors that could either be used to enhance enzyme/prodrug gene 
therapy or potentiate the effect of pharmacological drugs, and 2) pharmacological induction 
of Cx expression and GJIC, which could be combined to enzyme/prodrug gene therapy.
Fig. 2. Different GJIC, BE and/or Cx-based gene therapy approaches. Connexins (Cx)
restoration could be performed either by direct gene delivery or by induction using
pharmacological drugs. The Cx tumor suppressing effect is then either GJIC-dependent or
independent (indep). Similarly, the BE-mediated cytotoxic effect of the enzyme/prodrug 
(E/P) approach could either be GJIC-dependent or independent. It could be improved by Cx
restoration or by pharmacological intervention. 
3.1 Combined enzyme/prodrug/connexin gene therapy 
A major hurdle facing the enzyme/prodrug approach proved to be the loss of connexins 
and GJICs in the target cells, the malignant ones. Therefore, increasing the levels of Cxs and
GJIC in cancer cells would result in a better response to BE-based gene therapy cytotoxicity.
Transfecting cells with vectors encoding viral thymidine kinase and connexin genes has 
proven efficient in many studies (Cirenei et al. 1998; Ghoumari et al. 1998; Marconi et al. 
2000; Tanaka et al. 2001a)(table 1). 
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Enzyme/Prodrug
system
Connexin Targeting 
Vector 
Cell type Reference 
HSVtk/GCV Cx43 Retroviral Glioblastoma 
(U-87) 
(Cirenei et al. 
1998) 
HSVtk/GCV Cx43 Plasmid Hepatocellular 
carcinoma 
cells (Hepa1-6)
(Ghoumari et 
al. 1998)
HSVtk/GCV Cx43 A Herpes
simplex viral 
vector (HSV) 
Glioblastoma
(U-87) and 
fibrosarcoma 
(L929) 
(Marconi et al. 
2000) 
HSVtk/GCV Cx26 Adenoviral 
multigenic 
Bladder cancer
(UM-UC-3 
and UM-UC­
14) 
(Tanaka et al. 
2001a) 
HSVtk/GCV Cx26 Retroviral Pancreatic 
tumor cells
(NP-9, NP-18,
NP-31)
(Carrio et al. 
2001) 
HSVtk/GCV Cx43 Plasmid Cervical 
cancer (Hela)
(Tanaka et al. 
2001c) 
HSVtk/GCV Cx43 Plasmid Cervical 
cancer (Hela)
(Duflot-
Dancer et al. 
1998) 
HSVtk/GCV Cx43 Retroviral Breast cancer
(MDA-MB­
435) 
(Grignet-
Debrus et al. 
2000) 
Table 1. Examples of gene therapy studies combining the enzyme/prodrug and Cx 
restoration approaches. 
Nevertheless, enforced expression of Cxs might not always be sufficient to alleviate the 
inefficiency of the enzyme/prodrug system. For example, in a study of the efficacy of the 
HSVtk/GCV system combined with overexpression of Cx26 in a panel of pancreatic tumor 
cells, not all cell lines showed improved CJIC or bystander cytotoxicity (Carrio et al. 2001). 
Inability of Cx43 to properly localize at the cell surface prevented human colon tumor cells
from being targeted by the BE and cytotoxicity of HSVtk (McMasters et al. 1998). The
localization of Cx43 and the level of gap junctions functionality were also found to influence
the BE in glioblastoma cells (Cottin et al. 2008). Therefore, a better understanding of the
mechanisms involved in the stability and trafficking of connexins as well as the process of 
gap junction formation is needed. In particular, connexins’ phosphorylation is an essential 
post-translational modification in their life cycle (Solan and Lampe 2009) and so are their 
stability and degradation by the lysosomal and proteasomal systems (Leithe and Rivedal 
2007). For example, abnormal trafficking and lysosomal degradation can impede with the 
function of Cx43 (Qin et al. 2003a). Apigenin, a cancer chemopreventive flavonoid, was able 
to improve the effect of HSVtk only after concurrent transfection with the Cx43 gene, which 
suggests that, unlike other chemicals, it affects gap junction functionality rather than 
inducing connexin expression (Touraine et al. 1998). It has also been suggested that different
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223Hopes and Disillusions in Therapeutic Targeting of Intercellular Communication in Cancer
connexins might have different abilities to modulate the BE. Cx32 and Cx26 were reported
to be significantly more effective than Cx43 at mediating the BE in cocultures of connexin­
expressing and HSVtk-expressing C6 glioma cells (Jimenez et al. 2006). 
Another issue that is not completely elucidated is the importance of targeting tumor cells to
express both the suicide gene and the connexin at the same time. It has been suggested that 
separate introduction of the HSVtk and connexin genes in tumor cells might have higher 
killing efficiency than simultaneous expression, as illustrated by transfection of HeLa cells
with Cx43 and HSVtk genes (Tanaka et al. 2001c). Interestingly, the Cx-expressing cells 
induce the Cx-devoid cells to contribute to GJIC through an unknown mechanism (Tanaka
et al. 2001b). This is an encouraging observation in view of the known heterogeneity of 
tumors or in situations where Cx-negative malignant cells are scattered within Cx-positive
normal tissues (i.e. gliomas), which means that gene therapy targeting of these tumors with 
the enzyme/prodrug system might still be efficient even when only a small subpopulation 
of tumor cells expresses connexins.
3.2 Combined connexins delivery and pharmacological treatments.
Modulating GJIC and Connexins has been used to sensitize to chemotherapy using a variety 
of pharmacological drugs (Figure 2). For example, Cx32 expression enhanced the sensitivity 
of human renal cell carcinoma (RCC) cells to vinblastine (VBL) in vitro and in vivo (Sato et al. 
2007c). Cx43 overexpression increased the sensitivity of the LNCaP prostate cancer cells to
tumor necrosis factor alpha (TNFalpha), anti-Fas antibodies, and TRAIL (Wang et al. 2007). 
Overexpression of Cx26 improved the growth suppressive effect of doxorubicin in prostate 
cancer cells (Tanaka and Grossman 2004). Restoring Cx43 expression in human glioblastoma
increased sensitivity to Etoposide, Paclitaxel (Taxol) and Doxorubicin, in a way that, 
paradoxically, seems GJIC-independent (Huang et al. 2001). Combining intratumoral 
injection of a Cx43-expressing vector and intravenous injection of Docetaxel (DTX) 
improved anti-tumor efficiency more than DTX alone (Fukushima et al. 2007). The
overexpression of Cx26 resulted in increased GJIC and enhanced cytotoxic BE of 
gemcitabine, a nucleoside analogue drug whose phosphorylated form is transmitted 
through gap junctions, in pancreatic cancer cells both in vitro and in mice (Garcia-Rodriguez
et al. 2011b). At low doses, PKI-166, a Her-2/Her-1 inhibitor and PP1, a Src family inhibitor, 
were shown to enhance the tumor-suppressive effect of Cx32 in human renal cell carcinoma
Caki-2 cells, partly through GJIC (Fujimoto et al. 2005b; Fujimoto et al. 2005a). As a last 
example, Cx32 expression also significantly potentiated the cytotoxicity of vinorelbine 
(VBN), in lung adenocarcinoma A549 cells (Sato et al. 2007a). 
3.3 Combined pharmacological restoration of connexins and gene therapy 
In addition to exogenous delivery of connexins, their expression can be increased using 
pharmacological treatments that affect different levels of gene regulation. The strategy of 
restoring Cx expression to favor BE-mediated cytotoxicity is mainly confronted to a flagrant 
misunderstanding of the mechanisms of loss of Cx expression in cancer. Many 
transcriptional and post-transcriptional aberrations have been described so far but, as
expected, none provide a ubiquitous explanation (Carystinos et al. 2003; Gao et al. 2007;
Villares et al. 2009; Leithe and Rivedal 2007; Solan and Lampe 2009). Nevertheless, the 
available knowledge has significantly been used in a therapeutic perspective. 
Transcriptional silencing of Cx expression has been shown to involve epigenetic events such 
as promoter methylation and chromatin acetylation. Restoration of Cx32 in  human RCC
www.intechopen.com
  
 
 
  
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
224 Gene Therapy - Developments and Future Perspectives 
cells by 5-aza-2'-deoxycytidine (5-aza-CdR), a DNA demethylating agent, suppressed tumor 
growth in a xenograft model (Hagiwara et al. 2008). 4-phenylbutyrate (4-PB), a histone
deacetylases inhibitor (HDACi), induced connexin expression and enhanced GJIC between
pancreatic cancer cells in culture and potentiated HSVtk/GCV bystander killing effect in 
glioma cells (Ammerpohl et al. 2004; Ammerpohl et al. 2007). Other HDACi such as 
Trichostatin A (TSA) and sodium butyrate (NaBu), restored Cx43 expression and increased 
GJIC (Hernandez et al. 2006; Ammerpohl et al. 2007). It is not known if these HDACi would 
affect the outcome of the suicide gene therapy. Some of the compounds might also affect the 
BE independently of their gene expression-modulatory functions. N-butyrate, an inducer of 
histone hyperacetylation, was shown to enhance the GJIC and the BE in GJIC-deficient 
glioma cells independently from its HDACi function (Robe et al. 2004). 
Post-transcriptional regulation of Cx expression via mRNA trafficking, stability, splicing 
and translation, are probably the least studied aspects of Cx life cycle and their impact in
gene therapy improvement is still far-fetched. There is fortunately little more data on post-
translational regulation, especially protein modification and degradation by proteasomal 
and lysosomal mechanisms (Kjenseth et al. 2010; Berthoud et al. 2004). Additional
regulatory mechanisms include microRNA (Anderson et al. 2006) (Yang et al. 2007; Kedde et
al. 2007). In addition, an active Cx43 pseudogene (PsiCx43) has been identified and found to 
be expressed in breast cancer cell lines but not in normal breast epithelial cells (Kandouz et
al. 2004). Inhibition of this pseudogene using short interfering RNAs (siRNAs) can be used 
to restore Cx43 expression, thus improving chemosensitization of breast cancer cells (Bier et 
al. 2009). Although there are ways to specifically target these different pathways to restore
Cx expression, it is not known whether this would succeed in enhancing the BE cytotoxicity. 
In principle at least, connexins could also be targeted  via various interaction partners that
affect their localization, turnover and function such as the interaction of Cx30 with
cytoskeletal (microtubules, actin filaments) and tight/adherens junction proteins (Carette et 
al. 2009; Qu et al. 2009) or the interaction of Cx43 with the Rab GAP-like protein CIP85 (Lan 
et al. 2005). 
3.4 Combined pharmacological/gene therapy 
Another strategy is the use of chemical inducers of Cx expression to improve the efficiency 
of the enzyme/prodrug gene therapy (Figure 2). The inhibition of ATP-sensitive potassium 
(KATP) channels with tolbutamide resulted in increased Cx43 and GJIC, enhancing the 
bystander effect in HSVtk/GCV therapy in U373 human glioma cells (Paino et al. 2010). All-
trans retinoic acid was shown to induce Cx43 expression and to increase GJIC in tumor cell
lines, resulting in an increased efficiency of the HSVtk/GCV-induced cytotoxicity in vitro 
and in vivo (Park et al. 1997). A similar result was observed after 8-bromo-cyclic-AMP 
treatment, (Carystinos et al. 1999; Kunishige et al. 1998). This approach has particularly been 
viewed as a chemopreventive one (King and Bertram 2005). The green tea flavonoid 
compound (–)Epicatechin, prevents tumor promoting chemicals such as the 12-O­
tetradecanoylphorbol-13-acetate (TPA) from inhibiting GJIC (le-Agha et al. 2002).
Resveratrol (3,5,4'-trihydroxy-stilbene), a natural polyphenol, provides a similar preventive 
effect against TPA and the insecticide DDT (Nielsen et al. 2000), and so do carotenoids 
(Zhang et al. 1991). It is yet to be examined whether these treatments could increase the 
cytotoxic potential of the HSVtk/GCV and other gene therapy systems, but we could
already infer from the available data that pharmacologic upregulation of Cxs and gap 
junctions could be useful to combine with these gene therapy systems in clinical trials.
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4. GJIC-independent and BE-independent connexin cytotoxic effects
Part of the reasons why the original strong faith in the strategy to target connexins in the
treatment of human tumors has been shaken is due to the focus on the BE and GJIC only.
However, it is now obvious that in many contexts, the tumor suppressor effect of Cxs’
overexpression is GJIC-independent (Li et al. 2008b). Cx43 affect angiogenesis in vitro and in 
vivo (McLachlan et al. 2006) and improves the resistance to the chemotherapeutic agent
cisplatin (CDDP) (Sato et al. 2009) in a GJIC-independent fashion. Cx26 regulates 
angiogenesis-related molecules by mechanisms that are both GJIC-dependent and – 
independent (Kalra et al. 2006; Qin et al. 2003b). GJIC-independent functions of Cx32 in
blocking proliferation, invasion and metastasis in human renal cell carcinoma RCC cells, 
have also been reported (Sato et al. 2007b). Therefore, connexins could be used in gene
therapy regardless of their ability to trigger BE or GJIC (Figure 2). The exact mechanisms
and conditions where this strategy would be most effective are yet to be determined. 
5. Targeting tumor cells through GJIC with their cellular environment 
Another advantage of BE-based gene therapy strategies is that treatment could be aimed not 
only to the tumor cells but also to cellular partners within the microenvironment such as 
stromal and endothelial cells. For instance, when HSVtk-transduced endothelial cells and
non-HSVtk-transduced tumor cells were co-cultured, treatment with GCV resulted in the
BE-dependent death of both endothelial and tumor cells in vitro and in vivo (Trepel et al.
2009). Targeting human umbilical vein endothelial cells (HUVECs) with a Cx37-encoding 
adenovirus induced their death by apoptosis (Seul et al. 2004). 
Although largely hypothetical at this point, we can envision a strategy where GJIC between 
tumor and stromal cells would be enforced to render tumor cells susceptible to cell killing. 
In other words, targeting tumor-associated endothelial cells for example, with delivery of 
connexins and an enzyme/prodrug system, could result in the demise of both the tumor 
and its irrigating blood vessels. Using a tridimensional model of cell culture, Benalalam et 
al. showed that GJIC between endothelial and tumor cells are required for antigenic peptide 
transfer to endothelial cells resulting in the latter’s recognition and elimination by cytotoxic 
T cells (CTL) (Benlalam et al. 2009). Using the attraction of bone marrow-derived stem cells 
(BMSCs) for glioma cells, Huang et al. took advantage of GJIC between the two cell types to 
improve the efficiency of the HSVtk/GCV suicide gene therapy. Indeed, combining the
expression of HSVtk by BMSCs and the expression of Cx43 by glioma cells enhanced the 
bystander effect and improved suicide gene therapy (Huang et al. 2009). Similarly,
the formation of gap junctions between adipose-tissue derived human mesenchymal stem
cells (AT-MSC) and human glioblastoma cells contributed to bystander cytotoxicity of
HSVtk (Matuskova et al. 2009). 
Paradoxically, GJIC-enabled bystander cells have been shown to confer protection against 
GCV to the very HSVtk-transduced cells that are the source of the cytotoxic signal. The 
impact of this observation on the therapeutic efficacy is not known. Indeed, as suggested by 
the authors of this study, it can either increase the efficacy of the treatment, by decreasing 
the demise of the HSVtk cells, thus prolonging their cytotoxic effect, or have an opposite 
effect by increasing their survival (Wygoda et al. 1997). Nevertheless, this observation shows 
that the so-called “bystander cells” and their ability to communicate by GJIC are an 
important element to take into consideration in the BE-based therapy. This applies to tumor 
cells as well as the stromal cells with which they communicate.
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226 Gene Therapy - Developments and Future Perspectives 
The therapeutic potential of the neural stem cells (NSCs) in the treatment of brain tumors
have been demonstrated and, in many reports, have been shown to rely on bystander effect.
NSCs are highly migrating cells able to cross the blood–brain barrier and which show
tropism for tumor cells. Many studies showed that NSCs can be genetically modified to 
target tumor cells and the use of the cytosine deaminase (CD)/5-fluorocytosine (5-FC)
system delivered particularly important results in medulloblastomas and gliomas (Aboody
et al. 2000; Shimato et al. 2007; Kim et al. 2006) as well as breast or melanoma metastases to
the brain (Joo et al. 2009; Aboody et al. 2006). Combined delivery of the CD/5-FC system 
with Interferon-β (IFN-β), known for its anti-tumor effects, showed a stronger bystander 
killing effect in glioma both in vitro and using an orthotopic xenograft in vivo model, where 
animals were intravenously infused with CD/IFN-β-expressing NSCs and administred with 
the prodrug 5-FC (Ito et al. 2010). Also, migratory HSVtk-transduced NSCs were able to kill
untransduced glioma cells by a GJIC-mediated BE (Uhl et al. 2005). 
An additional level of complexity is the formation of different types of GJICs between 
different cell types. Homotypic gap junction channels formed of identical connexons and 
heterotypic channels made of connexons containing different connexins (Vaney and Weiler 
2000; Kapoor et al. 2004) can show different permeabilities (Weber et al. 2004; Bevans et al. 
1998b). This implies that Cx-mediated gene therapy will necessitate an elaborate 
“customization” effort to target specific interactions and avoid non specific effects. For 
instance, transformed cells form GJICs between them that are independent of the GJICs 
formed within adjacent nontransformed cells, with apparently no heterologous
communication (Yamasaki and Katoh 1988). Therefore, it is in principle possible to target
cancer-specific GJIC compartments without affecting normal cells.
6. Clinical trials 
Many clinical trials have been performed to validate the enzyme/prodrug gene therapy 
approach and test its effects. These include the trial of adenovirus mediated delivery of
HSVtk combined with GCV treatment in operable primary or recurrent high-grade gliomas,
which resulted in a clinically and statistically significant increase in mean patient survival 
(Immonen et al. 2004). A phase I dose escalation clinical trial was conducted in 11 men with 
localized recurrent and metastatic hormone-refractory prostate cancer. In this trial, an 
adenovirus vector carrying osteocalcin promoter-driven HSVtk was used to target both 
prostate cancer cells and their neighboring stromal cells and valacyclovir, another anti­
herpetic prodrug converted to aciclovir, was given orally. The results showed a good
tolerance with no serious adverse events but with local cell death in treated lesions in 63.6% 
of patients (Kubo et al. 2003). In another clinical phase I/II study, 36 prostate cancer patients 
with local recurrence after radiotherapy which received single or repeated cycles of 
adenoviral vector-mediated HSVtk/GCV intraprostatic gene therapy (Miles et al. 2001) 
showed no significant side effects and a significant increase in biological responses such as
the mean serum PSA-doubling time (PSADT), prostate-specific antigen recurrence (PSAR), 
return to initial PSA (TR-PSA), and activated CD8(+) T cells present in the peripheral blood. 
In another phase I trial, nine courses of intraprostatic injections of adenoviral HSVtk 
followed by intravenous injection of GCV in 8 patients with local recurrence of prostate 
cancer after definitive hormonal therapy, showed no adverse events and a significant
prolongation of the median serum PSADT. In five patients, decrease of PSA values was also 
observed (Nasu et al. 2007). Also, intraperitoneal administration of an HSVtk-encoding 
www.intechopen.com
  
 
 
 
 
 
 
  
 
  
 
 
 
 
  
  
 
 
  
  
 
  
 
  
 
  
 
227Hopes and Disillusions in Therapeutic Targeting of Intercellular Communication in Cancer
adenovirus and intravenous GCV showed significant efficacy in women with recurrent 
ovarian cancer (Alvarez et al. 2000). Finally, an adenoviral vector encoding the HSVtk gene
was also used in a phase I trial where it has been introduced into the pleural cavity of
patients with malignant mesothelioma in combination with systemic GCV treatments and
showed good tolerance and detectable gene delivery (Sterman et al. 1998). 
Most of these clinical trials focused on issues of tolerance of the therapy and efficacy of 
delivery. Although it is understood that these gene therapy attempts rely mainly on the BE, 
it is frustrating that no data is available that correlates these clinical results with the
formation of gap junctions and Cx expression in the targeted tumors. 
7. Conclusion 
Bystander effect is a big step forward in attempts to use gene therapy in cancer treatment. 
The idea that one can kill more cells than initially targeted has been a revolutionary concept.
However, the biggest challenge to the translation of this concept into an effective therapy 
has been the lack of information in many aspects surrounding the BE and the role of GJIC
and connexins. As further basic science studies are performed, we will be able to
comprehend the mechanisms of loss of Cx expression in cancer and how they could be
alleviated. Whether and how these mechanisms could be used to improve gene therapy is, 
again, wide open to exploration. An immediate impact of these studies would be the
analysis of tumors for GJIC or Cx expression to identify a subset of patients most likely to 
benefit from gene therapy using enzyme/prodrug systems such as HSVtk/GCV.
Other potential strategies could make use of the ability of gap junctions to transmit different 
types of cytotoxic signals. Radiotherapy for instance could benefit from this knowledge,
based on the finding that death signals could be transmitted through BE from irradiated to
nonirradiated cells (Azzam et al. 2001; Prise and O'Sullivan 2009). Radiation therapy could
be combined with gene therapy interventions aimed at increasing GJIC which would 
amplify the cellular responsiveness to radiation therapy 
The function of gap junction channels involves conductance and electrical and chemical 
gating that can be affected by many factors, including the nature and stoichiometry of the 
contributing connexins, ensuring selective permeability to various molecules (Saez et al. 
2010; Nakagawa et al. 2010; Bevans et al. 1998a). In theory, BE-based gene therapy combined 
with Cx expression restoration would benefit from identifying Cxs with the best 
conductance in specific cancer settings. Furthermore, it would be possible to introduce
specific mutations that would improve the conductance of BE cytotoxic molecules. Another 
possibility is to regulate opening and closure of gap junctional channels. The search for 
chemical inhibitors has delivered a series of drugs that result in either opening or closure of
gap junctions (Salameh and Dhein 2005). Another approach involved the use of mimetic 
peptides that bind to connexin hemichannels, and modify their conductance (Evans and
Leybaert 2007). Although it is yet to be assessed, targeting GJ opening and conductance 
properties could optimize the effect of the BE gene therapy.  However, again, the relevance 
to cancer of channel gating functions of connexins versus GJIC-independent functions is a 
major unknown. Although this pharmacological approach is most likely to be successful in
diseases such as arrhythmia or seizure, where hyperpolarization is a major issue, its possible
impact in cancer therapy, especially in combination with gene therapy, should not be 
excluded. 
Another issue of potential importance in improving the efficiency of the BE-based gene
therapy is the nature of metabolites that could or could not be transmitted by BE as
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illustrated by the differential ability of pyrimidine nucleoside analogues such as GCV to
pass the gap junctions and trigger cytotoxicity (Degreve et al. 1999). Enzyme/prodrug 
combinations involving pyrimidine analogues (BVDU, BVaraU) presented smaller 
bystander killing than the combination involving the purine analogue (GCV) (Grignet-
Debrus et al. 2000). 
In addition to connexins, another family of proteins called pannexins is increasingly being 
scrutinized for their ability to form gap junctions (D'hondt et al. 2009). Unless and until their 
role in cancer and GJIC has been clearly established, the only GJIC-based therapeutic
strategies will likely keep focusing on connexins.
Finally, so far only clinical trials on localized malignancies have been conducted, such as 
direct intra-tumoral injection of the vector in glioma therapy. Future studies are necessary to
develop intravenous delivery of viral vectors in the enzyme/prodrug gene therapy
approach, to allow targeting of other cancers. In addition, these Phase I trials have mainly 
addressed safety, toxicity and gene delivery issues. Further assessment of the anti-tumor 
effects and the correlation with GJIC and connexin expression should absolutely be on the 
list of future clinical trials. Combinations of these gene therapy approaches with other 
cancer therapeutic modalities should also be considered.
In summary, the promises of the Bystander effect, GJIC and Connexin-based gene therapies
are still alive. It is possible that the great enthusiasm for their potential was so high that it 
blinded us to the urgency of further examination of their mechanisms and regulations 
which, once performed, would much significantly improve the rationalization of the clinical
application and outcome. 
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